Payment overview · 2025
General Payments
$377.96
15 reported records · 6 companies
Healthcare provider profile · identity verified
David H Good, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WAGONER, OK · NPI 1780009969
Verified facts
What the public records show
CMS Open Payments records show David H Good, D.O. received $377.96 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 64.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $242.14 | 64.1% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.79 | 18.5% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $24.08 | 6.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.66 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.83 | 3.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.46 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.96 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $206.55 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.79 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 118 |
| Lisinopril | Lisinopril | 357 | 103 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 346 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 345 | 102 |
| Gabapentin | Gabapentin | 310 | 81 |
| Omeprazole | Omeprazole | 300 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 77 |
| Furosemide | Furosemide | 269 | 92 |
| Losartan Potassium | Losartan Potassium | 252 | 73 |
| Potassium Chloride | Potassium Chloride | 234 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 64 |
| Carvedilol | Carvedilol | 207 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 206 | 70 |
| Trazodone Hcl | Trazodone Hcl | 202 | 62 |
| Mounjaro | Tirzepatide | 192 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 55 |
| Metformin Hcl | Metformin Hcl | 168 | 45 |
| Azithromycin | Azithromycin | 159 | 132 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 48 |
| Montelukast Sodium | Montelukast Sodium | 157 | 47 |
| Donepezil Hcl | Donepezil Hcl | 139 | 34 |
| Sertraline Hcl | Sertraline Hcl | 134 | 38 |
| Cefdinir | Cefdinir | 133 | 96 |
| Eliquis | Apixaban | 132 | 32 |
| Clonidine Hcl | Clonidine Hcl | 125 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 24 |
| Buspirone Hcl | Buspirone Hcl | 119 | 36 |
| Meloxicam | Meloxicam | 116 | 32 |
| Levofloxacin | Levofloxacin | 114 | 90 |
| Simvastatin | Simvastatin | 109 | 31 |
| Alendronate Sodium | Alendronate Sodium | 106 | 33 |
| Baclofen | Baclofen | 104 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 29 |
| Allopurinol | Allopurinol | 102 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 34 |
| Glipizide | Glipizide | 99 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 97 | 68 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 20 |
| Ozempic | Semaglutide | 94 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 26 |
| Ibuprofen | Ibuprofen | 89 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 19 |
| Methylprednisolone | Methylprednisolone | 78 | 65 |
| Jardiance | Empagliflozin | 77 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 21 |
| Trulicity | Dulaglutide | 75 | 17 |
| Pregabalin | Pregabalin | 70 | 21 |
| Spironolactone | Spironolactone | 69 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 17 |
| Levetiracetam | Levetiracetam | 66 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 21 |
| Ondansetron Odt | Ondansetron | 59 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 51 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 15 |
| Vraylar | Cariprazine Hcl | 52 | 12 |
| Atenolol | Atenolol | 50 | suppressed |
| Nifedipine Er | Nifedipine | 50 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | 11 |
| Famotidine | Famotidine | 49 | 12 |
| Glimepiride | Glimepiride | 49 | 12 |
| Sucralfate | Sucralfate | 48 | 16 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Naproxen | Naproxen | 47 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 13 |
| Topiramate | Topiramate | 44 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 34 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 36 |
| Doxepin Hcl | Doxepin Hcl | 42 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Irbesartan | Irbesartan | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 11 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 16 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Torsemide | Torsemide | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Nystatin | Nystatin | 34 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 24 |
| Metronidazole | Metronidazole | 32 | 22 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 20 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | 12 |
| Celecoxib | Celecoxib | 26 | 11 |
| Finasteride | Finasteride | 26 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Lacosamide | Lacosamide | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Digoxin | Digoxin | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | 11 |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Pindolol | Pindolol | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.96 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, NURTEC ODT, VRAYLAR, XIFAXAN, XYOSTED, YUPELRI, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error